Upland, CA, United States of America

Love Volkova


Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 45(Granted Patents)


Company Filing History:


Years Active: 2012-2016

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Love Volkova: Innovator in Spinal Muscular Atrophy Research

Introduction

Love Volkova is a notable inventor based in Upland, CA, who has made significant contributions to the field of genetic research, particularly in the treatment of spinal muscular atrophy (SMA). With a total of 2 patents, Volkova's work focuses on innovative approaches to enhance the expression of survival motor neuron genes.

Latest Patents

Volkova's latest patents include groundbreaking inventions aimed at addressing SMA. The first patent, titled "Survival motor neuron gene (SMN2) mRNA constructs for post-transcription regulation," provides compounds and assays for identifying and validating treatments that up-regulate the post-transcriptional expression of SMN1 or SMN2. The second patent, "Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation," also focuses on compounds that enhance the expression of these critical genes, offering new avenues for therapeutic intervention.

Career Highlights

Love Volkova is currently associated with PTC Therapeutics, Inc., a company dedicated to developing innovative treatments for rare diseases. His work at PTC Therapeutics has positioned him as a key player in the ongoing research and development of therapies for SMA.

Collaborations

Volkova collaborates with talented professionals in the field, including Anuradha Bhattacharyya and Bansri S Furia, who contribute to the advancement of research initiatives aimed at improving patient outcomes.

Conclusion

Love Volkova's innovative work in the realm of spinal muscular atrophy research exemplifies the impact of dedicated inventors in the medical field. His contributions through patents and collaboration with esteemed colleagues continue to pave the way for potential breakthroughs in treatment options for SMA.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…